Personalized genetic therapy for ALS linked to CHCHD10 gene
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This trial tests a personalized treatment designed for one patient with ALS (Lou Gehrig's disease) caused by a specific genetic change. The therapy aims to target the genetic cause, potentially slowing the disease, and this study will help learn if it's safe and beneficial.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed genetic diagnosis related to the CHCHD10 gene (a type of ALS)
- You must be able to travel to the study site and follow the study schedule and procedures
- You cannot be taking any other experimental medication within 5 half-lives before starting the study
- You must give informed consent (or have a legal guardian do so) to participate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized medicine approach for people with a specific genetic form of ALS caused by changes in the CHCHD10 gene. A custom-designed antisense oligonucleotide (a type of genetic therapy) is used to target the underlying cause of the disease.
This trial tests a medication called acamprosate to see if it can slow down ALS in people who have a specific genetic change (C9orf72). If you have this gene change and ALS, this study might offer a new treatment option.
This trial tests a new treatment aimed at restoring the function of a gene called UNC13A in people with ALS. It involves multiple clinic visits, MRI scans, and spinal taps to see if the treatment is safe and may slow the disease.
This trial studies an experimental drug called LTX-002 for people with ALS. It aims to see if the drug is safe and can slow down the disease.
This trial tests a single injection of a gene therapy called INS1202 into the spinal fluid. It is for people with ALS, including those with a specific genetic form (SOD1 mutation). The goal is to see if it is safe and how it affects the body.
This trial tests a personalized medicine approach for people with ALS caused by changes in the TARDBP gene. The treatment uses a custom-made molecule to target the genetic cause and may help slow the disease.
Hear when a new Amyotrophic Lateral Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.